Eli Lilly & Co. (LLY) – Credit Ratings
-
Eli Lilly & Co. (LLY) Outlook Revised to Stable From Negative at S&P
-
Lilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody's
-
No Impact on Lilly's (LLY) Ratings Following Actos Verdict - Fitch
-
Fitch Raises Outlook on Eli Lilly (LLY) to Stable; Affirms Ratings
-
Fitch cuts Eli Lilly (LLY) to A; outlook raised from Negative to Stable
Back to LLY Stock Lookup